Breast Cancer Treatment
Cutting-Edge Test Development
We are dedicated to providing clinically useful, cost-effective testing strategies for patient care. Development, validation, and implementation of new and improved laboratory methods are major components of that commitment. Each assay, whether developed on site or by others, undergoes an extensive validation and performance documentation period before the test becomes available for clinical use.
Tests Announced in the June Communiqué
Nucleophosmin Mutation Analysis
- Useful
For:As a prognostic indicator in patients with newly diagnosed AML with normal karyotype and no
FLT3 mutation. - Unit Code: 89292
- Useful For:Influencing the target dose of methylphenidate treatment for patients with attention deficit/hyperactivity disorder and determining possible cause for poor response to methylphenidate in treated patients with attention deficit/hyperactivity disorder
- Unit Code: 89096
Additional Information
The June Communiqué feature: Update on Celiac Disease: New Standards and New Tests
More information on new and updated tests is available under Test Notifications.
External link
PDF document
Excel document
Word document